More than half of Americans, roughly 54% of the population, are living with a neurological disease or disorder, according findings detailed in a new study.
Spanish brain-computer interface (BCI) company INBRAIN Neuroelectronics has announced its collaboration with Microsoft to explore AI applications for real-time brain-computer interface therapeutics.
Scientists have found that immersive virtual reality may offer a way to replicate some of the psychological benefits associated with psychedelic substances, but without the use of any drugs.
Neuralink has moved to validate its controversial brain-implant technology in the scientific arena by submitting its first study for peer review and publication.
INBRAIN Neuroelectronics has partnered with Mayo Clinic to advance graphene-based brain-computer interface therapies, expanding into the U.S. while navigating differing European and FDA regulatory pathways.
The rapidly expanding brain-computer interface (BCI) field is not only driving cutting-edge neuroscience but also fueling a competitive race for market dominance.